Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 20:2:15.
doi: 10.1186/s40345-014-0015-8. eCollection 2014.

Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis

Emanuel Severus  1 , Matthew J Taylor  2 , Cathrin Sauer  1 , Andrea Pfennig  1 , Philipp Ritter  1 , Michael Bauer  1 , John R Geddes  3
Affiliations

Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis

Emanuel Severus et al. Int J Bipolar Disord. .

Abstract

Background: In a previous meta-analysis of randomized controlled trials comparing lithium with placebo as a long-term treatment in bipolar disorders, we observed a clear preventative effect for manic episodes; however, the effect was equivocal for depressive episodes. Since then, the evidence base has grown further. In this update, we furthermore present the data on efficacy of lithium in comparison to alternative drug treatments. In addition, we analyze the data comparing lithium with placebo and other treatments regarding drop-outs due to reasons other than a mood episode and completion of study (no mood episode and no drop-out to reasons other than a mood episode).

Methods: Randomized controlled trials (RCTs) were sought comparing lithium with placebo and lithium with an alternative treatment in bipolar disorders where the stated intent of treatment was prevention of mood episodes. To this purpose, the Cochrane Central Register of Controlled Trials (CENTRAL) was searched. Reference lists of relevant papers and major textbooks of mood disorders were examined. Authors, other experts in the field, and pharmaceutical companies were contacted for knowledge of suitable trials, published or unpublished.

Results: For the comparison of lithium with placebo, seven trials (1,580 participants) were included. Lithium was more effective than placebo in preventing overall mood episodes (random effects RR 0.66, 95% CI 0.53 to 0.82), manic episodes (random effects RR 0.52, 95% CI 0.38 to 0.71), and, dependent on the type of analyses applied, depressive episodes (random effects RR 0.78, 95% CI 0.59 to 1.03; fixed effect RR 0.73, 95% CI 0.60 to 0.88). Lithium was inferior to placebo in leading to drop-outs for reasons other than a mood episode (random effects RR 1.33, 95% CI 1.07 to 1.65) but superior to placebo on study completion (random effects RR 1.69, 95% CI 1.12 to 2.55). For the comparison of lithium with anticonvulsants, seven trials were included (n = 1,305). In prevention of manic episodes, lithium showed superiority compared to anticonvulsants (random effects RR 0.66, 95% CI 0.44 to 1.00). However, there was no significant difference regarding prevention of overall mood episodes, depressive episodes, dropping-out to reasons other than a mood episode, or study completion.

Conclusions: The evidence base for lithium in the long-term treatment of bipolar disorders has strengthened. With no other drug available having such ample and consistent evidence for its efficacy lithium remains the most valuable treatment option in this indication.

Keywords: Anticonvulsants; Bipolar disorders; Lithium; Long-term treatment; Meta-analysis; Placebo; Randomized controlled trial; Systematic review.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA flowchart of the inclusion procedure.
Figure 2
Figure 2
Prevention of any episode in bipolar disorders patients in RCTs comparing lithium with placebo.
Figure 3
Figure 3
Prevention of depressive/manic episodes in bipolar disorders patients in RCTs comparing lithium with placebo.
Figure 4
Figure 4
Discontinuation of study due to reasons other than a mood episode in bipolar disorders patients in RCTs comparing lithium with placebo.
Figure 5
Figure 5
Study completion in bipolar disorders patients in RCTs comparing lithium with placebo.
Figure 6
Figure 6
Prevention of any episode in bipolar disorders patients in RCTs comparing lithium with anticonvulsants.
Figure 7
Figure 7
Prevention of depressive/manic episodes in bipolar disorders patients in RCTs comparing lithium with anticonvulsants.
Figure 8
Figure 8
Discontinuation of study due to reasons other than a mood episode in bipolar disorders patients in RCTs comparing lithium with anticonvulsants.
Figure 9
Figure 9
Study completion in bipolar disorders patients in RCTs comparing lithium with anticonvulsants.
See this image and copyright information in PMC

References

    1. Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium? J Affect Disord. 1986;10(2):115–125. doi: 10.1016/0165-0327(86)90034-0. - DOI - PubMed
    1. Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry. 2010;167(7):792–800. doi: 10.1176/appi.ajp.2009.09020284. - DOI - PMC - PubMed
    1. Bauer M, Crossley NA, Gerber S, Bschor T. The acute antidepressive effects of lithium: from monotherapy to augmentation therapy in major depression. In: Bauer M, Grof P, Müller-Oerlinghausen B, editors. Lithium in Neuropsychiatry. The Comprehensive Guide. London: Informa Healthcare; 2006. pp. 109–128.
    1. Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs. 2014;28(4):331–342. doi: 10.1007/s40263-014-0152-8. - DOI - PubMed
    1. Blackwell B, Shepherd M. Prophylactic lithium: another therapeutic myth? An examination of the evidence to date. Lancet. 1968;1(7549):968–971. doi: 10.1016/S0140-6736(68)90917-3. - DOI - PubMed